Tarsus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	17.45	25.82	57.03	0	0	0
Revenue Growth (YoY)	-32.42%	-54.73%	-	-	-	-
Cost of Revenue	1.59	0.96	2.08	0	0	0
Gross Profit	15.85	24.86	54.95	0	0	0
Selling, General & Admin	108.7	44.95	25.4	8.17	1.14	0.45
Research & Development	50.31	42.62	41.71	18.83	3.16	0.9
Operating Expenses	159.01	87.57	67.11	27	4.3	1.35
Operating Income	-143.16	-62.71	-12.16	-27	-4.3	-1.35
Interest Expense / Income	3.35	2.2	0	0	-0.04	0.03
Other Expense / Income	-10.61	-2.82	1.62	-0.19	0.41	-0.06
Pretax Income	-135.89	-62.1	-13.77	-26.81	-4.67	-1.32
Income Tax	0	-0	0.06	0	0	0
Net Income	-135.89	-62.09	-13.83	-26.81	-4.67	-1.32
Shares Outstanding (Basic)	29	25	21	6	2	2
Shares Outstanding (Diluted)	29	25	21	6	2	2
Shares Change	19.35%	19.78%	231.12%	162.72%	34.29%	-
EPS (Basic)	-4.62	-2.52	-0.67	-4.32	-1.98	-0.75
EPS (Diluted)	-4.62	-2.52	-0.67	-4.32	-1.98	-0.75
Free Cash Flow	-123	-49.54	3.16	-21.59	-3.85	-1.19
Free Cash Flow Per Share	-4.19	-2.01	0.15	-3.48	-1.63	-0.68
Gross Margin	90.87%	96.30%	96.36%	-	-	-
Operating Margin	-820.53%	-242.92%	-21.32%	-	-	-
Profit Margin	-778.89%	-240.51%	-24.25%	-	-	-
Free Cash Flow Margin	-704.96%	-191.88%	5.54%	-	-	-
EBITDA	-131.13	-59.11	-13.17	-26.56	-4.64	-1.29
EBITDA Margin	-751.58%	-228.95%	-23.09%	-	-	-
Depreciation & Amortization	1.42	0.79	0.61	0.25	0.07	0
EBIT	-132.55	-59.9	-13.77	-26.81	-4.71	-1.29
EBIT Margin	-759.71%	-232.01%	-24.15%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).